SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 201.02+0.4%2:13 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (21855)6/4/1998 10:10:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
Here's what BARS had to say about the ONTAK market potential:
We believe that there are approximately 8,000 patients in the United States
with CTCL resistant to other course of therapy-- the target market for Ontak.
- We estimate that $50 million in U.S. sales is doable for this product.
- Thus, even if the penetration rate is low, we believe that Ontak
will be accretive to Ligand's earnings in 1999.
- Currently, we estimate that Ontak could sell approximately
$30-40 million in the U.S. and another $10-20 million
overseas.
- Lilly will receive a double-digit royalty from Ligand
for sales in the year 2000 and beyond.
- We believe this is a low-double digit royalty.
- Furthermore, we believe that there is significant potential for this
compound beyond CTCL, specifically in the non-Hodgkin's
lymphoma (NHL) market where the compound has demonstrated
potential.
- In a Phase I trial of 17 non-Hodgkin's lymphoma patients
treated with Ontak, two patients demonstrated a partial
response rate and one patient had a complete response.
- We estimate that the worldwide market for non-Hodgkin's
lymphoma is in excess of $250 million.
- We believe that if Ontak is approved for CTCL that Ligand
could market the product for NHL with the publication of
positive clinical results.
- If Ontak does demonstrate positive results in NHL, we
believe that this indication could drive sales to about
$100 million.
- Overall, we believe that this panel meeting validated Ligand/Seragen's approach to

treating CTCL, and we expect the drug to be FDA approved by year end 1998.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News